Ana Carla O. R.
- Country
- Spain
- Department
- Hematology
Research Overview
- A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
- Phase II Evaluation of Mosunetuzumab Combined with CHOP Regimen in Treatment-Naïve Patients with Richter's Syndrome
- Phase 3 Open-Label Evaluation of Epcoritamab with Rituximab and Lenalidomide in Relapsed/Refractory Follicular Lymphoma
Data & Insights
Has run more than one trial at 148 of 336 partner sites.
Specializations
Lymphocytic Leukemia Research
The investigator specializes in treating Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), exploring innovative therapeutic combinations with targeted agents. Their work involves evaluating treatment approaches using novel combinations of targeted therapies.
- Fixed-duration treatment protocols
- Minimal residual disease monitoring
- Combined immunotherapy approaches
A particular focus lies in developing personalized treatment strategies based on individual patient response patterns.
Follicular Lymphoma Studies
The investigator conducts extensive research in Follicular Lymphoma treatment, including studies of both treatment-naïve and relapsed/refractory cases. Their work encompasses novel therapeutic combinations and comparative treatment approaches.
- Immunotherapy combinations
- Long-term treatment outcomes
- Novel therapeutic agents
The research extends to evaluating response rates and progression-free survival in various therapeutic combinations.
Advanced Blood Cancer Research
The investigator's expertise extends to treating complex blood cancers, including Richter's Syndrome and B-cell malignancies. Their research encompasses innovative treatment protocols and long-term therapeutic strategies.
- Treatment of transformed lymphomas
- Novel therapeutic combinations
- Long-term safety assessments
A significant focus is placed on developing effective treatments for aggressive and transformed lymphomas.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.